The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
Open accessAbstract
Objective: To assess the effects of the B lymphocyte stimulator (BLyS)–specific inhibitor belimumab on immunologic biomarkers, including B cell and T cell populations, and maintenance of antibody titers to prior vaccines in autoantibody‐positive systemic lupus erythematosus (SLE) patients. Methods: Pooled data from 2 phase III trials, the Study of Belimumab in Subjects with SLE 52‐week (BLISS‐52) and 76‐week (BLISS‐76) trials, comparing belimumab 1 mg/kg or 10 mg/kg versus placebo (plus standard SLE therapy for each group) were analyzed for changes in autoantibody, immunoglobulin, and complement levels. BLISS‐76 patients were also analyzed for changes in B cell and T cell populations and effects on prior vaccine‐induced antibody levels. Results: Belimumab‐treated patients experienced significant sustained reductions in IgG and autoantibodies and improvement in C3/C4 levels, resulting in greater positive‐to‐negative conversion rates for IgG anti–double‐stranded DNA (anti‐dsDNA), anti‐Sm, anticardiolipin, and anti–ribosomal P autoantibodies and normalization of hypergammaglobulinemia and low C3/C4 levels. Belimumab‐treated patients experienced significant decreases in the numbers of naive and activated B cells, as well as plasma cells, whereas memory B cells and T cell populations did not decrease. Belimumab did not substantially affect preexisting antipneumococcal or anti–tetanus toxoid antibody levels. Post hoc analysis showed greater reductions in SLE disease activity and the risk of severe flares in patients treated with belimumab 10 mg/kg (P ≤ 0.01) who were anti‐dsDNA positive and had low C3/C4 levels at baseline. Normalization of the C3 or anti‐dsDNA level by 8 weeks, irrespective of therapy, was predictive of a reduced risk of severe flare over 52 weeks. Conclusion: Belimumab appears to promote normalization of serologic activity and reduce BLyS‐dependent B cell subsets in serologically and clinically active SLE. Greater serologic activity may predict a better treatment response to belimumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL
Litinskiy, M. B., Nardelli, B., Hilbert, D. M., He, B., Schaffer, A., Casali, P., & Cerutti, A. (2002) · Nature Immunology · doi:10.1038/ni829 · Cited by 1,252
RetractedDevelopment of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Self-citationEpidemiology and Prevention of Vaccine-Preventable Diseases
Atkinson, W. W. (2009) · Cited by 1,862
Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Self-citationRahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J., & Browning, J. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1697 · Cited by 1,480
BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth
Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J.-L., Holler, N., Ambrose, C., Lawton, P., Bixler, S., Acha-Orbea, H., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1747 · Cited by 1,333
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,174
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999) · Science · doi:10.1126/science.285.5425.260 · Cited by 1,144
Rahman, M. U. (2008) · Essentials of Physical Medicine and Rehabilitation · doi:10.1016/b978-1-4160-4007-1.50153-x · Cited by 1,019
(1997) · PsycEXTRA Dataset · doi:10.1037/e547512006-001 · Cited by 1,000
Cheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Self-citationCutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
Baff Mediates Survival of Peripheral Immature B Lymphocytes
Batten, M., Groom, J., Cachero, T. G., Qian, F., Schneider, P., Tschopp, J., Browning, J. L., & Mackay, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.10.1453 · Cited by 704
Manson, J. J., & Rahman, A. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-6 · Cited by 605
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice
Khare, S. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050580697 · Cited by 590
Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus
Schur, P. H., & Sandson, J. (1968) · New England Journal of Medicine · doi:10.1056/nejm196803072781004 · Cited by 587
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24699 · Cited by 585
Self-citationTer Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068841 · Cited by 567
Gordon, C., Li, C. K., & Isenberg, D. A. (2010) · Medicine · doi:10.1016/j.mpmed.2009.10.006 · Cited by 565
TACI and BAFF-R mediate isotype switching in B cells
Castigli, E., Wilson, S. A., Scott, S., Dedeoglu, F., Xu, S., Lam, K.-P., Bram, R. J., Jabara, H., & Geha, R. S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20032000 · Cited by 544
Novel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citationCutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL
Benson, M. J., Dillon, S. R., Castigli, E., Geha, R. S., Xu, S., Lam, K.-P., & Noelle, R. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3655 · Cited by 478
Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response
Do, R. K. G., Hatada, E., Lee, H., Tourigny, M. R., Hilbert, D., & Chen-Kiang, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.953 · Cited by 431
Petri, M., Stohl, W., Chatham, W., McCune, W. J., Chevrier, M., Ryel, J., Recta, V., Zhong, J., & Freimuth, W. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23678 · Cited by 428
Self-citationThompson, J. S., Schneider, P., Kalled, S. L., Wang, L., Lefevre, E. A., Cachero, T. G., MacKay, F., Bixler, S. A., Zafari, M., Liu, Z.-Y., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.129 · Cited by 394
Jacobi, A. M., Odendahl, M., Reiter, K., Bruns, A., Burmester, G. R., Radbruch, A., Valet, G., Lipsky, P. E., & Dörner, T. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10949 · Cited by 361
Jacobi, A. M., Huang, W., Wang, T., Freimuth, W., Sanz, I., Furie, R., Mackay, M., Aranow, C., Diamond, B., & Davidson, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27189 · Cited by 243
Self-citationSLE—a disease of clearance deficiency?
Munoz, L. E., Gaipl, U. S., Franz, S., Sheriff, A., Voll, R. E., Kalden, J. R., & Herrmann, M. (2005) · Rheumatology · doi:10.1093/rheumatology/keh693 · Cited by 202
BAFF is a survival and maturation factor for mouse B cells
Rolink, A. G., Tschopp, J., Schneider, P., & Melchers, F. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200207)32:7<2004::aid-immu2004>3.0.co;2-5 · Cited by 198
Tseng, C., Buyon, J. P., Kim, M., Belmont, M. H., Mackay, M. C., Diamond, B., Marder, G. S., Rosenthal, P., HAINES, K. A., Ilie, V., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22198 · Cited by 158
Halpern, W., Lappin, P. B., Zanardi, T. A., Cai, W., Corcoran, M. L., Zhong, J., & Baker, K. P. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj148 · Cited by 158
The socioeconomic burden of SLE
Lau, C. S., & Mak, A. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.106 · Cited by 137
Badr, G., Borhis, G., Lefèvre, E. A., Chaoul, N., Deshayes, F., Dessirier, V., Laprée, G., Tsapis, A., & Richard, Y. (2008) · Blood · doi:10.1182/blood-2007-03-081232 · Cited by 114
From BILAG to BLIPS—disease activity assessment in lupus past, present and future
Isenberg, D. A., & Gordon, C. (2000) · Lupus · doi:10.1191/096120300672904669 · Cited by 109
Tardivel, A., Tinel, A., Lens, S. M. A., Steiner, Q., Säuberli, E., Wilson, A., Mackay, F., Rolink, A. G., Beermann, F., Tschopp, J., et al. (2004) · European Journal of Immunology · doi:10.1002/eji.200324692 · Cited by 97
Petri, M., Singh, S., TESFASYONE, H., & MALIK, A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090019 · Cited by 89
Cited by
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
B-cell biology and development
Pieper, K., Grimbacher, B., & Eibel, H. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.046 · Cited by 615
Tipton, C. M., Fucile, C. F., Darce, J., Chida, A., Ichikawa, T., Gregoretti, I., Schieferl, S., Hom, J., Jenks, S., Feldman, R. J., et al. (2015) · Nature Immunology · doi:10.1038/ni.3175 · Cited by 581
Guidelines for the use of flow cytometry and cell sorting in immunological studies *
Cossarizza, A., Chang, H., Radbruch, A., Akdis, M., Andrä, I., Annunziato, F., Bacher, P., Barnaba, V., Battistini, L., Bauer, W. M., et al. (2017) · European Journal of Immunology · doi:10.1002/eji.201646632 · Cited by 542
Self-citationThe BAFF/APRIL system in SLE pathogenesis
Vincent, F. B., Morand, E. F., Schneider, P., & Mackay, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.33 · Cited by 448
Metadata
- Authors
- Stohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., Clarke, A., Aranow, C., Wellborne, F. R., Abud‐Mendoza, C., Hough, D. R., Pineda, L., Migone, T., Zhong, Z. J., Freimuth, W. W., Chatham, W. W., & Groups, O. B. O. T. B. A. B. S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-06-26
- Volume
- 64
- Issue
- 7
- Pages
- 2328-2337
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2106574491
- Cited by
- 418
- References
- 40
- FWCI
- 24.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.